In contrast, in several clinical studies with high-dose DAC an myelodysplastic syndrome (MDS). The treatment options of antileukaemic effect was seen with myelosuppression as the low-dose Ara-C and haematopoietic growth factors are disapmain toxic effect. [16][17][18] We conducted a phase II study with pointing in regard to response rate or response duration. We low-dose DAC to study the effectiveness of this drug in MDS 
comorbidity were entered in this study. All patients showed bad prognostic features such as high blast cell count in the bone marrow, anemia, thrombocytopenia or cytogenetic Introduction abnormalities related to a bad prognosis. 7, 8 Table 1 shows the characteristics of the patients. The median age was 72 years The myelodysplastic syndromes (MDS) consist of a hetero-(range 58-82 years). The following myelodysplastic subtypes geneous group of clonal haemopathies characterized by matuwere included: RA four, RARS two, RAEB 11, RAEB-T nine, ration defects resulting in ineffective haematopoiesis and so CMML one, secondary (sAML) two patients. The last two in various combinations of anemia, leucopenia and thrompatients were known to have progressive MDS but at entry to bocytopenia.
1,2 MDS frequently occur in elderly patients and the study their bone marrow revealed 30-40% of blasts, thus some of the cases are secondary or related to long-term bone they were scored as sAML. All patients but one (No. 25) were marrow damage after radiation or chemotherapy. 3, 4 Several blood and/or platelet transfusion-dependent. In 20 patients a studies delineating the course and the prognosis of MDS more or less severe comorbidity was present not affecting showed a poor median survival especially in patients with renal and/or hepatic function. CMML, RAEB and RAEB-T. 5, 6 A high blast cell count, the grade of (pan)cytopenia and some of the karyotypic abnormalities associated with MDS predict such a poor outcome. 7, 8 Therapy The treatment of MDS remains a challenge for the clinician, especially in elderly patients, because no currently available 5-Aza-2′-deoxycytidine (DAC) was a gift from Pharmachemie, therapy has been shown to be generally effective.
Haarlem, The Netherlands. In the first 21 patients DAC was 5-Aza-2′-deoxycytidine (DAC) is a pyrimidine analogue that given by continuous infusion for 72 h starting with a dose of inhibits DNA methylation.
9 It has been proposed that the inhi-50 mg/m 2 /24 h. Courses were repeated every 6 weeks when bition of DNA methylation by deoxycytidine analogues is no serious clinical problems other than (pan)cytopenia were responsible for gene activation and so to the induction of cell present. No dose reduction was allowed. The effect of DAC differentiation. 10 In several studies using either cell line therapy was evaluated by bone marrow aspirate and biopsy cells [11] [12] [13] or human leukaemic blasts 14 such a differentiationafter every second course. When after the first two courses a inducing effect was seen for DAC. In a small study with complete or partial response was observed two more courses 10 MDS patients low-dose DAC showed a 50% response rate;
with the same dose were given. When complete response (CR) the effect was claimed to be due to this differentiation effect. 15 was seen after the first two courses and evaluation after four courses showed persistent CR, therapy was stopped. copd, chronic obstructive pulmonary disease; chd, coronary heart disease; e.e.m., erythema exsudativum multiforme; d.m., diabetes mellitus; cva, cerebral vascular accident. Pretreated means that a form of chemotherapy was given previously. The diagnosis of MDS was made according to the criteria of the FAB classification: RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RAEB, refractory anemia with an excess of blasts; RAEB-T, refractory anemia with an excess of blasts in transformation; CMML, chronic myelomonocytic leukemia; sAML, secondary acute myeloid leukemia.
decreased and fixed dose of 40 mg/m 2 /24 h DAC was given a few months later and showed a stable disease for 126 weeks.
A response was seen in 15 patients (54%) ( Table 2 ). Eight of for 3 days with a maximum of six courses, because of the observed myelotoxicity in the first patients.
these 15 patients showed a complete response, five a partial response and two an improvement. Four patients had a stable disease during and after receiving six, five, seven and six courses of DAC respectively (see Table 2 for response Response criteria duration). In four patients we observed a leukaemic regrowth after one, one, three and one courses respectively. One of Complete response was defined as a normocellular or slightly hypocellular marrow with less than 5% blasts and normal the patients (No. 18) with a partial response after two courses showed a leukaemic regrowth after the fifth course of DAC. haemogram (Hb Ͼ11 g/dl; granulocytes Ͼ1.0 × 10 9 /l, platelets Ͼ100 × 10 9 /l). Partial response was defined as a Ͼ50% The actuarial median response duration was 31+ weeks (n = 15). Including those patients with stable disease (n = 19), decrease of marrow blast cell count together with an increase of Hb of at least 2 g/dl, a platelet count of Ͼ50 × 10 9 /l and the progression-free period was 33 weeks (range 6-83 weeks). Table 2 shows survival from start of therapy and the overall granulocytes Ͼ1.0 × 10 9 /l. We scored an improvement when the transfusion requirement decreased to at least 50% together survival from diagnosis. The actuarial median survival from start of therapy was 46 weeks. The actuarial overall median with some improvement of the peripheral cell count but not enough to qualify for PR. Stable disease was defined by the survival in this group was 28 months. It is of interest to note that we observed only one response (patient No. 12) among absence of CR, PR or improvement but without clear disease progression. The response duration was measured from the those patients with bad prognostic cytogenetic findings. As depicted in Table 2 we observed the first signs of response moment of best response.
after the first course of DAC in the majority of patients. (CR could officially be scored after bone marrow investigation that was done after the second course.) Two patients (Nos 8 and Results 16) showed a response only after the fifth and fourth course, respectively ( with normalisation of the peripheral blood cell count and one other adverse affects were seen. Three patients showed nausea WHO grade 2, another three had obstipation WHO grade 2. again a CR lasting for 4 months (patient No. 7).
In another three patients we observed psychosis (WHO grade 2/3) that may also be explained by their serious clinical condition with high fever (organic psycho syndrome) at that time.
Toxicity
No renal or pulmonary toxicity was observed. One patient showed an transient increase in liver transaminase level WHO In all patients severe pancytopenia was observed and myelotoxicity was the major adverse effect. In 16 patients, the myegrade 2. Hair loss or mucositis were not seen. One patient died of myocardial infarction after recovering from cytopenia, lotoxicity resulted in one or more infections of which several were serious and necessitating admission to hospital. Four thus probably not related to DAC. patients died of infection during such a pancytopenic period. Three of them had a bacterial sepsis and one an Aspergillus infection of the lung. One patient died of a cerebral haemorDiscussion rhage during thrombocytopenia. These five lethal complications were in fact the reason for decreasing the dose to Perhaps with the exception of allogenic bone marrow transplantation no currently available treatment has shown to be 40 mg/m 2 /24 h for 72 h. Two of the 16 patients showed a severe herpes zoster infection. No infections that exceeded WHO generally effective in producing sustained improvement of haematopoiesis or in delaying leukaemic evolution in patients grade 3 were observed after we started antibiotic prophylaxis during the pancytopenic period (patients 12-15 and 22-29).
with a myelodysplastic syndrome. High-dose chemotherapy with allogenic bone marrow transplantation can induce longIn those patients who showed a response, we were able to study the myelotoxicity in more detail. A nadir for the granuloterm complete remissions or even complete cure, but it can be used only in a minority of younger patients. 19, 20 Intensive cyte count was observed at a median on day 19 and for the platelets on day 15. The time to recovery for platelets polychemotherapy, eventually supported by autologous haematopoietic stem cell transplantation has been used in (Ͼ100 × 10 9 /l) was median 26 days (range 19-36 days; number of evaluable courses 26). Time to ANC Ͼ1.0 × 10 9 /l was younger patients, but its value has still to be proven, because in most studies the remission duration was short. 21, 22 At this median 36 days (range 19-47 days, n = 20). The number of transfusions given to patients was not scored. Some of the time there is no accepted standard therapy for elderly patients with MDS. In a review of the compiled data the average responding patients even needed transfusions after they showed response in order to overcome the cytopenic period response rate with low-dose chemotherapy with cytosine arabinoside (Ara-C) was only 17%. 23 Furthermore, in a large ranwhich indicates the myelotoxic effect of DAC. Hardly any 4 be incorporated in a new scoring system: a report on 408 cases.
domized study no survival benefit of low-dose Ara-C was seen we wondered if the responses seen were due to cell differen- low-dose Ara-C we think that myelotoxicity might be the 
